{
    "clinical_study": {
        "@rank": "47116", 
        "brief_summary": {
            "textblock": "To provide azithromycin for the treatment of individual patients with proven\n      cryptosporidiosis whose disease has persisted or progressed despite prior therapies."
        }, 
        "brief_title": "Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs", 
        "condition": [
            "Cryptosporidiosis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Cryptosporidiosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Cryptosporidiosis infection.\n\n          -  Life expectancy of at least 1 week.\n\n          -  Failed or been intolerant to prior therapy with standard antidiarrheal or antibiotic\n             or other therapies for cryptosporidiosis.\n\n          -  Consent of parent or guardian for patients under the legal age of consent. Patients\n             with documented favorable response to azithromycin under Pfizer protocol 066-143 may\n             receive maintenance therapy under this protocol.\n\n        Patients with persistent diarrhea requiring intravenous (IV) fluid therapy to maintain\n        hydration may receive IV azithromycin after approval by the clinical monitor. Patients\n        whose disease worsens despite a minimum of 2 weeks of oral therapy or patients whose\n        disease shows no improvement after 4 weeks of oral therapy will also be considered for a\n        trial period of intravenous azithromycin.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Known hypersensitivity or significant intolerance to macrolide antibiotics.\n\n          -  Eligibility and current treatment at a medical center performing study 066-143,\n             another study of azithromycin for treatment of cryptosporidiosis in AIDS patients.\n\n        Required:\n\n          -  Must have failed or been intolerant to prior therapy with standard antidiarrheal or\n             antibiotic therapies for cryptosporidiosis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002328", 
            "org_study_id": "058J", 
            "secondary_id": "066-167S"
        }, 
        "intervention": {
            "intervention_name": "Azithromycin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Azithromycin"
        }, 
        "keyword": [
            "Antidiarrheals", 
            "Cryptosporidiosis", 
            "Diarrhea", 
            "Acquired Immunodeficiency Syndrome", 
            "Azithromycin"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Groton", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06340"
                }, 
                "name": "Pfizer Central Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Oral/Intravenous Azithromycin in the Treatment of Cryptosporidiosis in Patients Whose Disease Has Not Been Controlled by Conventional Therapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002328"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1998"
    }, 
    "geocoordinates": {
        "Pfizer Central Research": "41.35 -72.079"
    }
}